Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

    Not Recruiting
  • participants needed
  • sponsor
    Catalysis SL
Updated on 19 August 2022
platelet count
white blood cell count
absolute neutrophil count
dietary supplementation
neutrophil count
pancreatic adenocarcinoma
cancer chemotherapy
nutritional supplement
leukocyte count
advanced pancreatic adenocarcinoma


The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.


To assess the effect of Ocoxin-Viusid on the quality of life of patients with advanced pancreatic adenocarcinoma.

To evaluate the effect of Ocoxin-Viusid on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid on tolerance to onco-specific therapy.

Identify the changes that occur in the nutritional status of patients receiving the supplement.

To evaluate the toxicity of Ocoxin-Viusid in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.

Condition Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
Treatment Ocoxin-Viusid®
Clinical Study IdentifierNCT03717298
SponsorCatalysis SL
Last Modified on19 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note